Opaleye Management, a 10% owner, buys $33,019 of Grace Therapeutics stock
What it means
- What to watch: The headline hangs on one number (10%) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $GRCE -1.66% in the latest session.
- Timing: It arrived overnight — the change beside it belongs to a session that had already packed up and gone home. Market holidays are not detected.
Where the stock stands
$GRCE last traded at $1.78, -1.66% on the session. That puts it 66% shy of its 52-week high of $5.18 and 6.6% clear of its low of $1.67 — within a tenth of its 52-week low. Over the year it has ranged 210% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $GRCE page.
How much coverage it is getting
Wook has logged 2 stories on $GRCE in the last 30 days, 1 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal — something has the newsroom's attention. Across those stories 0 read bullish, 2 neutral and 0 bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits squarely with the crowd. 2 of the 2 (100%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$GRCE earnings in 6 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the hard numbers get the last word soon.
What to watch next
The $GRCE page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $GRCE is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $GRCE. It carried $33,019 and 10%, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.